GRI GRI Bio, Inc.
GRI Bio Beat Consensus Estimates
GRI Bio (GRI) reported a loss of $0.69 per share on revenue of $0.00 million for the third quarter ended September 2026. The consensus estimate was a loss of $0.84 per share. The company beat consensus estimates by 17.86%.
GRI Bio Inc. is a clinical stage biopharmaceutical company which focused on fundamentally changing the way inflammatory, fibrotic and autoimmune diseases are treated. GRI Bio Inc., formerly known as Vallon Pharmaceuticals Inc., is based in PHILADELPHIA, PA.
*Reported earnings and revenue figures shown above, and any guidance given, are preliminary and may be updated upon further review.*